$DARE
Dare Bioscience, Inc.

2024 Q4 Form 10-Q Financial Statement

#000140191424000041 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $41.69K
YoY Change -95.83%
Cost Of Revenue $0.00
YoY Change
Gross Profit $41.69K
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $2.066M
YoY Change -24.03%
% of Gross Profit 4956.27%
Research & Development $2.657M
YoY Change -60.2%
% of Gross Profit 6372.68%
Depreciation & Amortization $9.740K
YoY Change -2.6%
% of Gross Profit 23.36%
Operating Expenses $4.723M
YoY Change -49.74%
Operating Profit -$4.681M
YoY Change -44.25%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$21.15K
YoY Change -121.73%
Pretax Income -$4.703M
YoY Change -43.34%
Income Tax
% Of Pretax Income
Net Earnings -$4.703M
YoY Change -43.34%
Net Earnings / Revenue -11279.42%
Basic Earnings Per Share -$0.55
Diluted Earnings Per Share -$0.55
COMMON SHARES
Basic Shares Outstanding 8.700M shares 8.546M shares
Diluted Shares Outstanding 8.534M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.23M
YoY Change -19.13%
Cash & Equivalents $11.20M
Short-Term Investments
Other Short-Term Assets $3.195M
YoY Change 284.27%
Inventory
Prepaid Expenses $3.195M
Receivables
Other Receivables $518.9K
Total Short-Term Assets $14.95M
YoY Change -33.38%
LONG-TERM ASSETS
Property, Plant & Equipment $706.3K
YoY Change 1104.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $533.9K
YoY Change -32.96%
Total Long-Term Assets $3.113M
YoY Change 18.87%
TOTAL ASSETS
Total Short-Term Assets $14.95M
Total Long-Term Assets $3.113M
Total Assets $18.06M
YoY Change -27.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.049M
YoY Change -78.97%
Accrued Expenses $1.851M
YoY Change -65.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.16M
YoY Change -50.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $6.388M
YoY Change 538.76%
Total Long-Term Liabilities $6.388M
YoY Change 538.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.16M
Total Long-Term Liabilities $6.388M
Total Liabilities $19.54M
YoY Change -28.52%
SHAREHOLDERS EQUITY
Retained Earnings -$169.8M
YoY Change 2.17%
Common Stock $168.7M
YoY Change 2.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.484M
YoY Change
Total Liabilities & Shareholders Equity $18.06M
YoY Change -27.92%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$4.703M
YoY Change -43.34%
Depreciation, Depletion And Amortization $9.740K
YoY Change -2.6%
Cash From Operating Activities -$5.924M
YoY Change -25.76%
INVESTING ACTIVITIES
Capital Expenditures -$282.3K
YoY Change -1511.6%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $282.3K
YoY Change -1511.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 436.4K
YoY Change -94.91%
NET CHANGE
Cash From Operating Activities -5.924M
Cash From Investing Activities 282.3K
Cash From Financing Activities 436.4K
Net Change In Cash -5.205M
YoY Change -997.47%
FREE CASH FLOW
Cash From Operating Activities -$5.924M
Capital Expenditures -$282.3K
Free Cash Flow -$5.642M
YoY Change -29.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8331161 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8331161 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8762232 usd
dei Entity File Number
EntityFileNumber
001-36395
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
926-7655
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10476056 usd
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
518886 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
949211 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3194776 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6118272 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
533942 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
599594 usd
CY2024Q3 us-gaap Assets
Assets
18058801 usd
CY2023Q4 us-gaap Assets
Assets
21282215 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1048679 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3385551 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1850862 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2889005 usd
CY2024Q3 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
9750360 usd
CY2023Q4 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
13737154 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
897790 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
935743 usd
CY2024Q3 us-gaap Liabilities
Liabilities
19543284 usd
CY2023Q4 us-gaap Liabilities
Liabilities
26329855 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
854 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
833 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-362625 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-360896 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
166548454 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169783232 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171236031 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5047640 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18058801 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21282215 usd
CY2024Q3 us-gaap Revenues
Revenues
41691 usd
CY2023Q3 us-gaap Revenues
Revenues
1000000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
us-gaap Revenues
Revenues
73431 usd
us-gaap Revenues
Revenues
1000000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2041268 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2696779 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7159979 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8954877 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2656772 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6674636 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10894066 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17738543 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8656856 shares
dei Document Type
DocumentType
10-Q
us-gaap Operating Expenses
OperatingExpenses
26768420 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4681349 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8396415 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
627700 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001401914
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
Dare Bioscience, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4139823
dei Entity Address Address Line1
EntityAddressAddressLine1
3655 Nobel Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 260
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
DARE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Assets Current
AssetsCurrent
14946271 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
17543539 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
706256 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
655975 usd
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
544499 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1163477 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1327833 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1319630 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
468726 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13155725 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20480436 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1000000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1000000 usd
CY2024Q3 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
4489769 usd
CY2023Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
3913676 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
168660520 usd
CY2024Q3 us-gaap Royalty Expense
RoyaltyExpense
0 usd
CY2023Q3 us-gaap Royalty Expense
RoyaltyExpense
0 usd
us-gaap Royalty Expense
RoyaltyExpense
7674 usd
us-gaap Royalty Expense
RoyaltyExpense
0 usd
CY2024Q3 dare License Fee Expense
LicenseFeeExpense
25000 usd
CY2023Q3 dare License Fee Expense
LicenseFeeExpense
25000 usd
us-gaap Operating Expenses
OperatingExpenses
18136719 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18063288 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-25768420 usd
CY2024Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
0 usd
CY2023Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
0 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
20379376 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
0 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21152 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
97319 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-863289 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
664591 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8299096 usd
us-gaap Net Income Loss
NetIncomeLoss
1452799 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
22935 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15030 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1729 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-68186 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4679566 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8314126 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25172015 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.45
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.45
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8534433 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7587637 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7587637 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8683610 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7268465 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5047640 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6755356 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-10999410 usd
us-gaap Net Income Loss
NetIncomeLoss
-25103829 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1451070 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7268465 shares
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-39227 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
562719 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
14563 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2671506 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
650186 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
452195 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-31151 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2719402 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
636086 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8108702 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8299096 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15030 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2288740 usd
us-gaap Net Income Loss
NetIncomeLoss
1452799 usd
us-gaap Net Income Loss
NetIncomeLoss
-25103829 usd
us-gaap Depreciation
Depreciation
35957 usd
us-gaap Depreciation
Depreciation
28383 usd
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0833
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0833
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8700389 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11232609 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
505824 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8546364 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8546364 shares
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1484483 usd
dare License Fee Expense
LicenseFeeExpense
75000 usd
dare License Fee Expense
LicenseFeeExpense
75000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4723040 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
9396415 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4702501 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8534433 shares
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
215113 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
182978 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
0 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
12910656 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
523577 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4702501 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
22935 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1484483 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11112110 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
624621 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1299375 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8042501 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22005 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4971600 usd
dare Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-350112 usd
dare Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-275549 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1713996 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1910893 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-600000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
dare Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
63725 usd
dare Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
0 usd
dare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
256295 usd
dare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
0 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-430325 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-573401 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2923497 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-86053 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
57063 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
1752975 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
0 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
831379 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-30653 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
24764 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-359171 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-294151 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-2336871 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
2959446 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1207805 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6068350 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
385432 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 usd
dare Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
3986794 usd
dare Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
2641232 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
205206 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
167637 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30677749 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10197 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22099 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10197 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22099 usd
dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
398091 usd
dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
8560897 usd
dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
1299375 usd
dare Repayment Of Liability On Sale Future Royalties
RepaymentOfLiabilityOnSaleFutureRoyalties
1910 usd
dare Repayment Of Liability On Sale Future Royalties
RepaymentOfLiabilityOnSaleFutureRoyalties
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
561663 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
601174 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
392002 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
133594 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
565842 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10327852 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1729 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-68185 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
721553 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20440181 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10811056 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34669605 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11532609 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14229424 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11232609 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13894424 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
300000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
335000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11532609 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14229424 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
358315 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
dare Additions To Property And Equipment And Reduction To Deposits
AdditionsToPropertyAndEquipmentAndReductionToDeposits
676041 usd
dare Additions To Property And Equipment And Reduction To Deposits
AdditionsToPropertyAndEquipmentAndReductionToDeposits
0 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain reclassifications have been made to the Company’s prior year amounts to conform to the current year presentation.</span></div>
CY2024Q3 dare Stockholders Equity Note Stock Split Conversion Basis Prior To Reverse Stock Split
StockholdersEquityNoteStockSplitConversionBasisPriorToReverseStockSplit
12 shares
CY2024Q3 dare Stockholders Equity Note Stock Split Conversion Basis After Reverse Stock Split
StockholdersEquityNoteStockSplitConversionBasisAfterReverseStockSplit
1 shares
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
300000 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
300000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169800000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11200000 usd
CY2024Q3 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
9800000 usd
CY2024Q3 dare Working Capital Deficit
WorkingCapitalDeficit
1800000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18100000 usd
us-gaap Net Income Loss
NetIncomeLoss
1500000 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
200000 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
20400000 usd
dare Periodof Insufficient Cashand Liquidity Requirements
PeriodofInsufficientCashandLiquidityRequirements
P12M
CY2024Q3 dare Stockholders Equity Note Stock Split Conversion Basis Prior To Reverse Stock Split
StockholdersEquityNoteStockSplitConversionBasisPriorToReverseStockSplit
12 shares
CY2024Q3 dare Stockholders Equity Note Stock Split Conversion Basis After Reverse Stock Split
StockholdersEquityNoteStockSplitConversionBasisAfterReverseStockSplit
1 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101100000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101100000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8500000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8500000 shares
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
36.00
CY2018Q1 dare Estimated Fair Value Of Warrants Recorded In Equity
EstimatedFairValueOfWarrantsRecordedInEquity
3000000.0 usd
CY2019Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
11.76
CY2020Q3 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
11.52
CY2024Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
2800000 usd
dare Weighted Average Amortization Period
WeightedAverageAmortizationPeriod
P1Y1M24D
CY2018Q3 us-gaap Net Rentable Area
NetRentableArea
3169 sqft
CY2024Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
400000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1300000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
194000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
585000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
125000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
409000 usd
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
160000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
479000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
105516 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
314774 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M1D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1050
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
137000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
660000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
680000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
130000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1607000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
203000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1404000 usd
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2171996 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1622532 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2145242 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1622532 shares
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001401914-24-000041-index-headers.html Edgar Link pending
0001401914-24-000041-index.html Edgar Link pending
0001401914-24-000041.txt Edgar Link pending
0001401914-24-000041-xbrl.zip Edgar Link pending
dare-20240930.htm Edgar Link pending
dare-20240930.xsd Edgar Link pending
dare-20240930_g1.jpg Edgar Link pending
exhibit311_20240930.htm Edgar Link pending
exhibit321_20240930.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
dare-20240930_def.xml Edgar Link unprocessable
dare-20240930_lab.xml Edgar Link unprocessable
dare-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dare-20240930_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dare-20240930_cal.xml Edgar Link unprocessable